KEM.

QS Ovar: A national quality assurance program in Germany

Prof Dr Philipp Harter

Director of the department of Gynecology & Gynecologic Oncology

Evangelische Kliniken Essen-Mitte, Essen

Chair of the AGO Study Group

Conflicts of interest
Philipp Harter

Honoraria: Amgen, Astra Zeneca, GSK, Roche, Immunogen, Sotio, Stryker, Zai Lab, MSD, Clovis, Miltenyi, Eisai, Mersana, Exscientia, Daiichi Sankyo, Karyopharm, Abbvie

Advisory Board: Astra Zeneca, Roche, GSK, Clovis, Immunogen, MSD, Miltenyi, Novartis, Eisai, Corcept, BionTech

Research Funding (Inst): Astra Zeneca, Roche, GSK, Genmab, DFG, European Union, DKH, Immunogen, Seagen, Clovis, Novartis, Immatics

Use of real world data – what is the intention?

- QS Ovar was started in 2000 to describe the treatment quality (surgery + chemotherapy) of patients with ovarian cancer in Germany
- The aim was to improve outcome of our patients
- Unfortunately, never supported by public funding….
- Pure academic motivation!

Method: All German hospitals treating patients with ovarian cancer were asked to document prospectively all patients with first diagnosis in the third quarter of the respective year. Details of tumor, treatment and outcome were documented.

About 60% of all patients with ovarian cancer diagnosed in Germany within the observation periods are included in this analysis.

FIGO Stage and year of diagnosis



Harter P, et al. ESMO Gyn 2024

FIGO I: Quality of staging surgery



Wimberger P, et al. DGGG 2024

FIGO I: Quality of surgery (DFS and OS)





Wimberger P, et al. DGGG 2024

Quality of Surgery: Timing and residual disease FIGO III-IV (only pts with surgery)



RD = Residual dise

Harter P, et al. ESMO Gyn 2024

Systemic primary therapy FIGO III-IV (only patients with chemotherapy)



- w/o platinum
- Platinum single agent
- Platinum + Maintenance*
- Platinum + Taxane

* Bevacizumab, PARPi or Bev.+PARPi



Harter P, et al. ESMO Gyn 2024

Maintenance therapy in high-grade FIGO III/IV in 2021 (only pts with chemotherapy)



m = mutated; wt = wild-type; uk = unknown; nt = not tested

Harter P, et al. ESMO Gyn 2024

Treatment and outcome of elderly patients (≥ 75 years)

- PFS and OS in pts with TR> 0 or no surgery: impact of CTX





The triage for or against surgery should be done with respect to subsequent CTX, whose omission seems to be the worst prognostic factor among the therapeutic modalities

Survival of OC patients with tumor but without CTX was 3 months